What ICH E6 (R3) Means for Document Management

The latest revision of the Good Clinical Practice guideline, ICH E6 (R3), updates how clinical trial documentation should be managed, with new expectations for compliance. New operational strategies and deployment of digital management systems will be vital to meet these new requirements. 

What Changed Compared to E6 (R2) 

E6 (R2) was largely prescriptive, designed for traditional site-based trials. It did not fully anticipate decentralized models, electronic records, or modern data governance. R3 moves toward a principles-based approach, emphasizing flexibility and proportionality. The 13 principles found in E6 (R2) have been revised and refocused to 11 core principles. These principles are more detailed and more flexible, with new guidelines for risk proportionality, roles and responsibilities, and data governance. 

Key updates include: 

• Risk-Based Proportionality: Trial processes, measures, and approaches should be scaled with trial complexity and risk. This fit-for-purpose approach to trial conduct aims to use quality-by-design to factor in risks to participants and clinical data reliability and reduce burden on participants and investigators. 

• Digital Readiness: R3 explicitly supports electronic records, eSignatures/eConsent, and remote monitoring. Electronic records used for clinical trials should be evaluated for their fit-for-purpose in the context of the trial. When these electronic methods are used for data capture and management, data verification and metadata retention, including audit trails, should be implemented. 

• Data Governance: Section 4 of E6 (R3) details requirements for data governance, highlighting the management of data integrity, traceability, and data security. Key processes required for successful data governance include the protection of participant confidentiality, computerized system management to ensure appropriate applications, safeguards for essential trial elements, like randomization and blinding, and support for key decision making. 

How an eQMS Helps Achieve Compliance 

An eQMS can play a central role in meeting these new requirements, provided that it is configured correctly. Here’s how: 

Flexible Workflows 

Your eQMS should allow configurable document workflows that adapt to different trial designs. For example, a low-risk observational study may require fewer approvals than a high-risk interventional trial. Quality systems that enforce rigid templates will need to be updated to a version that can provide this flexibility. 

Digital and Remote Capabilities 

With decentralized trials becoming common, document management must support electronic signatures and remote monitoring records. In addition, eQMS that can integrate with electronic data capture systems and capture traceability present additional benefits to trials operating at different locations. 

Metadata and Audit Trails 

E6 (R3) places strong emphasis on data integrity. For complete compliance, every document used in clinical trials should carry metadata such as version history, timestamps, and user actions. Audit trails must be complete and tamper-proof, ensuring transparency for regulators; additionally, there should be procedures in place for reviewing trial-specific data, audit trails and other relevant metadata.  

Role-Based Access and Oversight 

Roles in clinical trials should be clear and documented. An eQMS used for clinical trials should provide role-based permissions and dashboards for oversight. This ensures sponsors, CROs, and investigators can access what they need based on their duties and functions, all without compromising security. Limiting record access to users will also ensure attributability to each user. Like other metadata, authorized users and permissions should be documented and stored. 

Validation of Computerized Systems 

Keeping with the risk-based emphasis in this document, the computerized systems used in clinical trials should be validated throughout their lifecycle, with the extent of validation being dependent on the intended use of the system. Validation should take into account system completeness, accuracy, reliability, and performance; periodic re-validation may be necessary. 

Practical Steps for Companies 

Here are a few simple steps that companies can consider to prepare for their transition to E6 (R3) from R2: 

• Review current document management processes against R3 principles. 

• Update SOPs to reflect risk-based and digital-ready approaches. 

• Ensure your eQMS is updated and validated according to E6 (R3) requirements. 

• Train staff on new expectations, especially around metadata retention and audit trails. 

The Bigger Picture 

ICH E6 (R3) modernizes clinical research standards to support flexibility, digital tools, and participant-centered practices. Companies that adapt their eQMS to these changes will not only stay compliant but also strengthen data integrity and operational efficiency. Document management in clinical trials has now evolved to consider governance, connectivity, and readiness for the future of clinical trials. To read more about ICH E6 (R3), visit the official release from ICH, as well as discussions from research institutes like the NIHR. 

If you are interested in an eQMS solution with a dedicated clinical management module and a proven track record of quality and compliance, learn more about ACE, the all-in-one management platform covering quality, inspection, and clinical management, and more.